News List

Cipla launches Q-TIB globally, a single tablet for T.B. prophylaxis in HIV


Cipla has received approval for its Q-TIB from WHO. According to Cipla, Q-TIB will help prevent tuberculosis infection in people living with HIV

By Team ABLE

Pharma major Cipla Ltd, on November 30th had announced that the company has received an approval for its product Q-TIB from World Health Organisation (WHO).
Q-TIB is a novel fixed dose combination in a single tablet. This is the first time that such a combination has been made available in the world. Cipla says it will market the product globally.

According to Cipla, Q-TIB will help prevent tuberculosis infection in people living with HIV. People living with HIV face a challenged immune system and are prone to opportunistic infections, which constitute the major source of premature deaths among them.